Agid, Y., Javoy-Agid, F., Ruberg, M., Pillon, B., Dubois, B., Duyckaerts, C., et al. (1987) Progressive supranuclear palsy: anatomoclinical and biochemical considerations. Adv Neurol45: 191-206.
2.
Blier, P. (2006) Medication combination and augmentation strategies in the treatment of major depression. In: Stein, DJ, Kupfer, DJ, Schatzberg, AF (eds), The American Psychiatric Publishing Textbook of Mood Disorders. Washington DC: American Psychiatric Publishing Inc, pp. 509-524.
3.
Blier, P., Saint-André, E., Hébert, C., de Montigny, C., Lavoie, N., Debonnel, G. (2007) Effects of different doses of venlafaxine on serotonin and norepinephrine reuptake in healthy volunteers. Int J Neuropsychopharmacol10: 41-50.
4.
Castañeda, E., Whishaw, IQ, Robinson, TE (1990) Changes in striatal dopamine neurotransmission assessed with microdialysis following recovery from a bilateral 6-OHDA lesion: variation as a function of lesion size. J Neurosci10: 1847-1854.
5.
Curet, O., de Montigny, C. (1988) Electrophysiological characterization of adrenoceptors in the rat dorsal hippocampus. II. Receptors mediating the effect of synaptically released norepinephrine. Brain Res475: 47-57.
6.
Debonnel, G., Saint-André, E., Hébert, C., de Montigny, C., Lavoie, N., Blier, P. (2007) Differential physiological effects of a low dose and high doses of venlafaxine in major depression. Int J Neuropsychopharmacol10: 51-61.
7.
Dong, J., Blier, P. (2001) Modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion treatment. Psychopharmacology (Berl)155: 52-57.
8.
Farde, L., Nordström, AL, Wiesel, FA, Pauli, S., Halldin, C., Sedvall, G. (1992) Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry49: 538-544.
9.
Kirby, LG, Kreiss, DS, Singh, A., Lucki, I. (1995) Effect of destruction of serotonin neurons on basal and fenfluramine-induced serotonin release in striatum. Synapse20: 99-105.
10.
McGeer, PL, McGeer, EG, Suzuki, J., Dolman, CE, Nagai, T. (1984) Aging, Alzheimer's disease, and the cholinergic system of the basal forebrain. Neurology34: 741-745.
11.
Meyer, JH, Goulding, VS, Wilson, AA, Hussey, D., Christensen, BK, Houle, S. (2002) Bupropion occupancy of the dopamine transporter is low during clinical treatment. Psychopharmacology (Berl)163: 102-105.
12.
Meyer, JH, Wilson, AA, Sagrati, S., Hussey, D., Carella, A., Potter, WZ (2004) Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry161: 826-835.
13.
Owens, MJ, Krulewicz, S., Simon, JS, Sheehan, DV, Thase, ME, Carpenter, DJ, et al. (2008) Estimates of serotonin and norepinephrine transporter inhibition in depressed patients treated with paroxetine or venlafaxine . Neuropsychopharmacology Apr 16 [Epub ahead of print] PMID:18418363.
14.
Takano, A., Suzuki, K., Kosaka, J., Ota, M., Nozaki, S., Ikoma, Y., et al. (2006) A dose-finding study of duloxetine based on serotonin transporter occupancy. Psychopharmacology (Berl)185: 395-399.
15.
Tatsumi, M., Groshan, K., Blakely, RD, Richelson, E. (1997) Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol340: 249-258.
16.
Turcotte, JE, Debonnel, G., de Montigny, C., Hébert, C., Blier, P. (2001) Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects. Neuropsychopharmacology24: 511-521.
17.
Vincent, S., Bieck, PR, Garland, EM, Loghin, C., Bymaster, FP, Black, BK, et al. (2004) Clinical assessment of norepinephrine transporter blockade through biochemical and pharmacological profiles. Circulation109: 3202-3207.
18.
Zimmer, R. (1990) Relationship between tyramine potentiation and monoamine oxidase (MAO) inhibition: comparison between moclobemide and other MAO inhibitors. Acta Psychiatr Scand82 (Suppl. 360): 81-83.
